Supinoxin blocks small cell lung cancer progression by inhibiting mitochondrial respiration through DDX5

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Small cell lung cancer (SCLC) is a lethal and treatment-resistant cancer.
• DDX5, a DEAD-box RNA helicase, is overexpressed in SCLC and crucial for its invasive growth and mitochondrial respiration.
• Effective treatments for SCLC are limited.

Purpose of the Study:

• To investigate the anti-cancer activity of Supinoxin (RX 5902) in SCLC.
• To determine the mechanism of action of Supinoxin, focusing on its interaction with DDX5 and cellular energy metabolism.

Main Methods:

• Assessed Supinoxin's effect on proliferation in chemo-sensitive (H69) and chemo-resistant (H69AR) SCLC cell lines.
• Evaluated Supinoxin's efficacy in reducing tumor growth in H69AR xenografts and SCLC patient-derived xenografts (PDX) in vivo.
• Measured the impact of Supinoxin on mitochondrial gene expression and cellular respiration.

Main Results:

• Supinoxin inhibited proliferation in both chemo-sensitive and chemo-resistant SCLC cell lines.
• Supinoxin significantly mitigated tumor growth in both xenograft and PDX models.
• Supinoxin treatment led to reduced expression of mitochondrial genes and impaired cellular respiration.

Conclusions:

• Supinoxin demonstrates significant anti-cancer activity against SCLC, including chemo-resistant forms.
• The anti-tumor effects of Supinoxin are mediated by the inhibition of DDX5 and subsequent reduction in cellular energy levels via mitochondrial dysfunction.
• Supinoxin represents a promising therapeutic candidate for SCLC by targeting energy metabolism.